medication and quality improvement Archives

Abstract Number: 2858 • ACR/ARHP Annual Meeting 2018
Gaps in Patient Safety Performance before Treatment with Biologic Disease-Modifying Antirheumatic Drugs or Tofacitinib in a Large Academic Healthcare System
Sarah L. Patterson¹, Michael Evans², Ishita Aggarwal³, Zara Izadi⁴, Milena Gianfrancesco⁵, Gabriela Schmajuk⁶ and Jinoos Yazdany⁷, ¹Division of Rheumatology, University of California, San Francisco, San Francisco, CA, ²University of California - San Francisco, San Francisco, CA, ³Medicine, Santa Clara Valley Medical Center, San Jose, CA, ⁴Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, ⁵Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ⁶San Francisco VA Medical Center, San Francisco, CA, ⁷University of California, San Francisco, San Francisco, CA
Background/Purpose: Treatment with biologic disease-modifying antirheumatic drugs (DMARDs) and tofacitinib confer increased risk of life-threatening infections, including reactivation of latent tuberculosis infection (LTBI), hepatitis B…
Abstract Number: 2107 • ACR/ARHP Annual Meeting 2014
Characterization of Social Stigma in Rheumatic Diseases and Correlation with Quality of Life and Medication Adherence
Gihyun Myung^1,2, Nancy D. Harada^3,4, Stephanie L. Fong¹, Cleopatra Aquino-Beaton^1,5 and Meika A Fang⁶, ¹VA Greater Los Angeles Healthcare System, Los Angeles, CA, ²Cedars-Sinai Medical Center, Los Angeles, CA, ³UCLA David Geffen School of Medicine, Long Beach, CA, ⁴VA Office of Academic Affiliations, Long Beach, CA, ⁵UCLA School of Nursing, Los Angeles, CA, ⁶Rheumatology, VA Greater Los Angeles Healthcare System, Los Angeles, CA
Background/Purpose Patients with rheumatoid arthritis and other rheumatic conditions may have physical deformities and functional limitations which make them vulnerable to health-related stigma. The objectives…

Abstracts tagged "medication and quality improvement"

Gaps in Patient Safety Performance before Treatment with Biologic Disease-Modifying Antirheumatic Drugs or Tofacitinib in a Large Academic Healthcare System

Characterization of Social Stigma in Rheumatic Diseases and Correlation with Quality of Life and Medication Adherence